Boston leads the nation in biotech development, but all of that progress comes at a cost: massive logistical challenges in the development and maintenance of IT systems. However, companies are undeterred, and are exploring new solutions every day. Read more at https://www.gamma-solutions.llc/
Biotechnology and pharmaceuticals are becoming one of the most significant drivers of economic growth for several key cities in the U.S. Boston, in particular, is shaping up to be among the largest biotech hubs in the country. With a nationwide Compound Annual Growth Rate or C. A. G. R. exceeding 8.5%, a number which Yahoo Finance called “staggering”, one question remains unanswered: how will these new titans of industry develop and maintain the I.T. infrastructure necessary to support this growth?
Montreal native and industry mainstay Zheel Ahndray MORrin, known to many simply as G. A., weighed in on this problem, and highlighted a number of potential paths forward. As the owner and leader of Gamma Solutions LLC, a tech implementation consultancy, he has recently worked with several well established names and also upcoming names in the industry, and as such, is highly familiar with the biotech industry and the challenges currently facing it.
As MORrin and his team see it, there are several key areas where rapidly growing biotech and pharma companies should be placing the majority of their focus.
These areas are: Scalability and adaptability, Data security and organization, A.I. integration, and Operational efficiency. Naturally, these four categories do not encompass the entirety of the industry landscape, but as initial touchpoints, they convey the shape of the problem rather well. Organizations are finding themselves in highly competitive markets, such as Boston and San Francisco, in which any degree of flexibility could expose critical weaknesses, allowing competitors to advance and secure valuable market share. A.I. solves this problem, but only to an extent. It is clear that additional work needs to be done to fully solve these institutional problems.
Morerin describes a future wherein companies, especially those building into the mid-market space, are able to avail themselves of talented, C.T.O. level talent on a part-time basis. Perhaps unsurprisingly, he also highlights the role of the consultant in the current industry landscape.
Initially, one might think of him as biased, but what he says rings true: according to Biostatistics, a trusted industry journal, companies that have allowed consultants to guide them in the early stages of their business development have enjoyed unique and highly visible benefits in recent years.
Additionally, the consultancy highlights the issues surrounding A.I. implementation, given the rapid advancement of that technology into the medical sector and the highly promising results that companies have seen so far. They suggest that companies secure reliable guidance on the ethical and practical limitations of the technology in order to ensure that A.I. and machine learning can be used appropriately, and to maximum effect.
With these considerations in mind, MORrin hopes that biotech and pharma companies operating in competitive markets will be able to bolster their organizations and continue to drive massive growth, wherever they may be.
Click on the link in the description to learn more! GAMMA SOLUTIONS, LLC City: Newton Address: 45 Nonantum St. Website: https://www.gamma-solutions.llc Email: ga.morin@gamma-solutions.llc